| human | Q5 |
| P496 | ORCID iD | 0000-0003-0334-1479 |
| P3829 | Publons author ID | 2733758 |
| P1053 | ResearcherID | D-9777-2012 |
| P1153 | Scopus author ID | 55555303800 |
| P734 | family name | Scott | Q12800811 |
| Scott | Q12800811 | ||
| Scott | Q12800811 | ||
| P735 | given name | Linda | Q1136594 |
| Linda | Q1136594 | ||
| P106 | occupation | researcher | Q1650915 |
| P21 | sex or gender | female | Q6581072 |
| Q38139915 | Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors |
| Q53563972 | Alpha4 and beta2 integrins have nonredundant roles for asthma development, but for optimal allergen sensitization only alpha4 is critical. |
| Q34988228 | Deletion of alpha4 integrins from adult hematopoietic cells reveals roles in homeostasis, regeneration, and homing. |
| Q38540370 | Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies |
| Q39901451 | Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders |
| Q42006793 | JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia |
| Q42742283 | Lack of alpha4 integrin expression in stem cells restricts competitive function and self-renewal activity |
| Q38075971 | Lymphoid malignancies: Another face to the Janus kinases. |
| Q34775393 | MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. |
| Q43757332 | Molecular pathways in bone marrow homing: dominant role of alpha(4)beta(1) over beta(2)-integrins and selectins |
| Q50721189 | Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation. |
| Q54531488 | Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients. |
| Q46355702 | Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome |
| Q50662979 | Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera. |
| Q38717569 | Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms. |
| Q50624557 | Rapid identification of JAK2 exon 12 mutations using high resolution melting analysis. |
| Q26859843 | Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research |
| Q37146068 | SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases |
| Q53959801 | Synergistic mobilization of hemopoietic progenitor cells using concurrent beta1 and beta2 integrin blockade or beta2-deficient mice. |
| Q35132280 | The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms |
| Q46735262 | The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders |
| Q46868807 | The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels |
| Q44881600 | Transgenic Cre expression mice for generation of erythroid-specific gene alterations |
| Q35847871 | VCAM-1 expression in adult hematopoietic and nonhematopoietic cells is controlled by tissue-inductive signals and reflects their developmental origin. |
Search more.